INTRODUCTION: There is little information on patient-driven noncompliance of adjuvant therapies and its consequences. METHODS: This retrospective study compares clinical, pathological features and outcomes of breast cancer patients who were compliant to recommended radiation, chemotherapy, and hormonal therapies to those who were noncompliant. RESULTS: Noncompliance rates for chemotherapy, radiation, and tamoxifen were 31 of 421 (7%), 30 of 855 (4%), and 294 of (37%) respectively. Old age was associated with noncompliance to chemotherapy and radiation, but younger women tend to be more often noncompliant to tamoxifen. Noncompliance with chemotherapy or radiation did not significantly affect 5-year local and distant disease-free survival rates. Noncompliance with tamoxifen was associated with decreased 5-year local and distant disease-free survivals (87% versus 96%, 76% versus 87%, respectively, P < .001). CONCLUSION: Noncompliance with tamoxifen is the most common, resulting in significantly increased risk of local and distant disease recurrence.
INTRODUCTION: There is little information on patient-driven noncompliance of adjuvant therapies and its consequences. METHODS: This retrospective study compares clinical, pathological features and outcomes of breast cancerpatients who were compliant to recommended radiation, chemotherapy, and hormonal therapies to those who were noncompliant. RESULTS: Noncompliance rates for chemotherapy, radiation, and tamoxifen were 31 of 421 (7%), 30 of 855 (4%), and 294 of (37%) respectively. Old age was associated with noncompliance to chemotherapy and radiation, but younger women tend to be more often noncompliant to tamoxifen. Noncompliance with chemotherapy or radiation did not significantly affect 5-year local and distant disease-free survival rates. Noncompliance with tamoxifen was associated with decreased 5-year local and distant disease-free survivals (87% versus 96%, 76% versus 87%, respectively, P < .001). CONCLUSION: Noncompliance with tamoxifen is the most common, resulting in significantly increased risk of local and distant disease recurrence.
Authors: P A Fasching; T Fehm; S Kellner; J de Waal; M Rezai; B Baier; G Baake; H-C Kolberg; M Guggenberger; M Warm; N Harbeck; R Würstlein; J-U Deuker; P Dall; B Richter; G Wachsmann; C Brucker; J W Siebers; N Fersis; T Kuhn; C Wolf; H-W Vollert; G-P Breitbach; W Janni; R Landthaler; A Kohls; D Rezek; T Noesslet; G Fischer; S Henschen; T Praetz; V Heyl; T Kühn; T Krauß; C Thomssen; S Kümmel; A Hohn; H Tesch; C Mundhenke; A Hein; C Rauh; C M Bayer; A Jacob; K Schmidt; E Belleville; P Hadji; D Wallwiener; E-M Grischke; M W Beckmann; S Y Brucker Journal: Geburtshilfe Frauenheilkd Date: 2014-12 Impact factor: 2.915
Authors: Gretchen Kimmick; Sara N Edmond; Hayden B Bosworth; Jeffrey Peppercorn; Paul K Marcom; Kimberly Blackwell; Francis J Keefe; Rebecca A Shelby Journal: Breast Date: 2015-07-16 Impact factor: 4.380
Authors: Joseph A Greer; Nicole Amoyal; Lauren Nisotel; Joel N Fishbein; James MacDonald; Jamie Stagl; Inga Lennes; Jennifer S Temel; Steven A Safren; William F Pirl Journal: Oncologist Date: 2016-02-26
Authors: Stephanie M Smith; Raymond R Balise; Catherine Norton; Mary M Chen; Alissa N Flesher; Alice E Guardino Journal: Patient Educ Couns Date: 2012-09-30
Authors: Ellen H Bailey; Maria Pérez; Rebecca L Aft; Ying Liu; Mario Schootman; Donna B Jeffe Journal: Breast Cancer Res Treat Date: 2009-11-21 Impact factor: 4.872